New York, New York (PRWEB) August 10, 2014
Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, such as Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to an Order issued on July 29, 2014, U.S. District Judge Anthony Battaglia has approved a deposition protocol for the proceeding. Among other things, the Order stipulates that witnesses to be deposed in the multidistrict litigation may be cross-notified for any other case pending in state or federal court in order to avoid duplicative depositions. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“Our Firm continues to hear from individuals who allege that Byetta and other incretin mimetics caused pancreatic cancer, as well as pancreatitis and thyroid cancer. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who may have been harmed by this drug.
Byetta Pancreatic Cancer Litigation
Court documents indicate that more than 460 claims, including dozens of Byetta lawsuits, are now pending in the incretin mimetics litigation underway in the Southern District of California. All of the lawsuits allege that the drugs’ manufacturers failed to warn doctors and patients about their potentially harmful effects on the pancreas, as well as their alleged association with an increased risk of pancreatic cancer.
In addition to the claims pending in the federal proceeding, court documents show that a number of Byetta lawsuits involving similar allegations have been consolidated in a state-level litigation underway in California Superior Court. (In re: Byetta Cases, JCCP No. 4574)
According to court records, the litigation surrounding incretin mimetics has been growing since March 2013, when the U.S. Food & Drug Administration (FDA) announced it was investigating findings from an unpublished study that indicated their use could be associated with cellular changes in the pancreas called pancreatic duct metaplasia, a precursor to cancer. Though the agency has been unable to conclude that such a link exists, its review is ongoing.
Just a month after the FDA announced its incretin mimetics review, the Institute for Safe Medicine Practices revealed that the FDA had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta in a single 12-month period. The same review also found that compared to other classes of diabetes medications, incretin mimetics were far more likely to be associated with pancreatic cancer.*
Individuals who took Byetta and developed pancreatic cancer, thyroid cancer or pancreatitis may be entitled to compensation for medical bills, lost wages, and pain and suffering. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.
*ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter
Felecia L. Stern, Esq.
Bernstein Liebhard LLP